Amniotic fluid-derived mesenchymal stem cells as a therapeutic tool against cytokine storm: a comparison with umbilical cord counterparts
The data presented here suggest that AF-MSCs hold significant promise for treating not only COVID-19-associated cytokine storms but also a variety of other inflammatory syndromes (i.e., those induced by bacterial infections, autoimmune disorders, and therapeutic interventions). Realizing the full potential of AF-MSCs as a comprehensive therapeutic approach in inflammatory disease management will require more extensive clinical trials and in-depth mechanistic studies.
Authors
- David W. James (ORCID: https://orcid.org/0000-0001-8798-2016)
- Salvatore Vaiasicca (ORCID: https://orcid.org/0000-0002-0160-1022)
- Bruna Corradetti (ORCID: https://orcid.org/0000-0002-0345-4847)
- Omar Saeed (ORCID: https://orcid.org/0000-0002-7290-2703)
- Lewis W. Francis (ORCID: https://orcid.org/0000-0002-7803-7714)
- Gianmarco Melone
Institutions
- Marche Polytechnic University (IT)
- Baylor College of Medicine (US)
- Swansea University (GB)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
- Istituto Nazionale di Riposo e Cura per Anziani (IT)
Publication Details
- Journal
- Stem Cell Research & Therapy
- Published
- 2025-03-28
- DOI
- https://doi.org/10.1186/s13287-025-04262-0
- Citations
- 1
- Primary Topic
- Mesenchymal stem cell research
- Type
- article
- Field-Weighted Citation Impact
- 1.63
Funders
- H2020 Marie Skłodowska-Curie Actions